

Synthesis and exploratory biological evaluation of 3-[(*N*-4-benzyloxyphenyl)iminoethyl]- and 3-(1-hydrazonoethyl)-4-hydroxycoumarins

Meloddy H. Manyeruke,^a Heinrich C. Hoppe,^{b,c} Michelle Isaacs,^c Ronnett Seldon,^d Digby F. Warner,^e
Rui W.M. Krause,^{a,c*} and Perry T. Kaye^{a,c*}

^aDepartment of Chemistry, ^b Department of Biochemistry and Microbiology and ^cCentre for Chemico- and Biomedical Research (CCBR), Rhodes University, Makhanda/Grahamstown, 6140, South Africa.

^dDrug Discovery and Development Centre (H3-D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa

^eMolecular Mycobacteriology Research Unit, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Email: P.Kaye@ru.ac.za; R.Krause@ru.ac.za


Received 03-17-2022

Accepted Manuscript 05-26-2022

Published on line 06-24-2022

Abstract

Three series of 4-hydroxycoumarin derivatives, comprising a total of 20 novel compounds have been prepared from 2-hydroxyacetophenones. These include a set of 3-[(*N*-4-benzyloxyphenyl)iminoethyl]-4-hydroxycoumarins, and two differently substituted sets of 3-(1-hydrazonoethyl)-4-hydroxycoumarins. The products were subjected to exploratory biological studies, and some of the compounds exhibited encouraging activity against the trypanosomal parasite *T.b. brucei*, two of them exhibiting IC₅₀ values of 0.90 μM and 27.88 μM.



Keywords: Synthesis, 4-hydroxycoumarins, imines, hydrazones, bioassay, anti-trypanosomal activity

Introduction

Naturally occurring and synthetic chromone (*2H*-1-benzopyran-2-one) derivatives comprise an important and extensive class of heterocyclic compounds. Reviewed by Sethna and Shah¹ more than 75 years ago, these compounds continue to enjoy the attention of synthetic and medicinal chemists and remain the subject of ongoing reviews.^{2,3} Coumarin derivatives are known to exhibit a broad range of medicinal properties, including anti-coagulant, anti-HIV, anti-cancer and anti-inflammatory activities, and inhibitory activity against important enzymes, such as monoamine oxidase and cyclooxygenase.⁴ Synthetic *N*-aryl coumarin-3-carboxamides have been evaluated^{5,6} for activity against human lung fibroblasts and breast cancer cell lines, and the most potent compound (with an IC₅₀ of 0.166 μM against ErbB-2 kinase) was the 6-chlorocoumarin derivative **1** (Figure 1). Küçükbay *et al.*⁷ have reported carbonic anhydrase inhibition by amino acid-coumarin conjugates at sub-micromolar concentrations. A common feature in many biologically active coumarin derivatives is the presence of a 4-hydroxy group, as in the anti-coagulant phenprocoumon **2**;⁸ in fact, this appears to be one of the minimum structural requirements for anti-coagulant activity in analogous systems.⁹ A series of hybrid coumarin derivatives, including the hydrazine derivative **3**, were shown to exhibit promising anti-HIV activity.¹⁰

Compounds containing an imino group have exhibited a range of biological activities, including anti-cancer,¹¹ anti-viral¹² and anti-β-secretase¹³ properties, while there appears to be growing interest in the medicinal potential of hydrazone derivatives.^{14,15} The alkyne moiety is present in a number of pharmaceuticals, including Efavirenz,¹⁴ an antiretroviral, and the antifungal agent Terbanafine.¹⁶





Figure 1. Biologically active coumarin derivatives **1**,⁵ **2**,⁷ **3**,⁸ and **4**.¹⁸

We have a close and ongoing interest in applications of Morita-Baylis-Hillman methodology in the synthesis of benzannulated heterocyclic systems in general¹⁷ and coumarin derivatives¹⁸ in particular. Attention has been given to the synthesis of novel furocoumarins **4** – designed to serve as HIV-1 Integrase inhibitors¹⁹ – and coumarin-AZT conjugates as portmanteau HIV-1 protease and reverse transcriptase inhibitors.²⁰ Access to 4-hydroxycoumarins, however, has required the application of a different methodology and, in a recent study,²¹ we made use of a procedure developed by Zhao *et al.*²² to access these systems. We now report the preparation and exploratory biological evaluation of three series of compounds containing 4-hydroxycoumarin, iminoethyl, hydrazoneethyl and alkynyl moieties.

Results and Discussion


Synthesis of 4-hydroxycoumarin derivatives

With minor modifications of the method reported by Zhao *et al.*,²² the 2-hydroxyacetophenones **5a-f** were reacted with diethyl or dimethyl carbonate in the presence of sodium hydride to afford the 4-hydroxycoumarins **6a-f** in yields of 60-87% (Scheme 1). Adapting a procedure described by Sukdolak *et al.*,²³ the 4-hydroxycoumarins **6a-f** were reacted with POCl₃ in acetic acid to give the 3-acetylated derivatives **7a-f** in yields ranging from 41% to 90%. Increasing the reaction time to at least 1 hour improved the yield, while washing the resulting precipitates with methanol gave the respective products in high purity thus obviating the need for recrystallisation. Each of the 3-acetyl-4-hydroxycoumarins **7a-f** was condensed with 4-benzyloxyaniline **8** (obtained by prior neutralisation of the hydrochloride salt) in an acetic acid-catalysed reaction in refluxing methanol for at least an hour. The resulting precipitates were filtered off, washed with methanol and dried to give the targeted products **9a-f** in high yield (82 - 94%) and high purity - as confirmed by NMR analysis.



Scheme 1. Synthesis of 3-[(N-4-benzyloxyphenyl)iminoethyl]-4-hydroxycoumarins **9a-f**.

The 3-acetyl-4-hydroxycoumarin **7a** was reacted with hydrazine hydrate under reflux for 1 hour using ethanol as the solvent and acetic acid as a catalyst to afford the hydrazone derivative **12** in 80% yield (Scheme 2). The deshielding of the OH signal (at 15.53 ppm) in the ¹H NMR spectrum of this compound is consistent with involvement of the hydrazone N¹ atom and the phenolic proton in a six-membered hydrogen-bonded chelate. The hydrazone **12** then provided access to two series of dihydrazone derivatives **13a-g** and **15a-g**. For the first series, the hydrazone **12** was reacted with each of seven disubstituted benzaldehydes **11a-g** in refluxing ethanol (to which a catalytic quantity of 2N-HCl had been added) to yield the novel 3-[1-(benzylidenehydrazono)ethyl]-4-hydroxycoumarins **13a-g** in moderate to good yields (51-76%). Four of the benzaldehyde precursors **11a-d** had been obtained in 65-75% yields by prior *O*-benzylation of their phenolic precursors **10a-d**; the other three benzaldehyde precursors (**11e-g**) were commercially available. For the second series, the hydrazone **12** was similarly reacted with each of the propargyloxy-substituted benzaldehydes **14a-g** to afford the corresponding 3-[1-(benzylidenehydrazono)ethyl]-4-hydroxycoumarins **15a-g** in good yields (65-80%).



Scheme 2. Synthesis of 3-[1-(benzylidenehydrazono)ethyl]-4-hydroxycoumarin analogues (**13**) and (**15**).

All of the novel compounds were fully characterised using HRMS, IR and 1-D and, where appropriate, 2-D NMR analytical data. Use of COSY and HSQC data, as illustrated in **Figures 2** and **3**, respectively, facilitated the assignment of ¹H- and ¹³C-NMR signals to the corresponding aromatic nuclei, with different and distinctive proton-proton coupling patterns, in the two benzenoid rings in compound **13f**. Interestingly, Milenko *et al.*²⁴ have reported the preparation of analogous compounds with very encouraging antimicrobial properties and have used NOE and HMBC experiments to confirm their structural identity. *In vitro* bioassay and molecular docking studies of closely related 3-hydroxycoumarin derivatives have been undertaken by Batran *et al.*²⁵ to investigate antifungal properties and by Abdel Latif *et al.*²⁶ to explore their anti-cancer potential.

Biological evaluation

The novel, synthetic products were screened for cytotoxicity against HeLa cells and, variously, for HIV-1 IN and PR enzyme inhibitory potential and for antimalarial, trypanocidal and anti-mycobacterial activity. The bioassay protocols and results for each series of products are provided in the Supporting Information file. The 3-[(*N*-4-benzyloxyphenyl)iminoethyl]-4-hydroxycoumarins **9a-f**, at 20 μM concentration, exhibited little if any significant cytotoxicity (< 50% viability of HeLa cells) nor activity against the malaria parasite (pLDH) – patterns generally common to the analogous benzylidenehydrazono series (**13**) and (**15**). Compounds **9a-d**, however, decreased the viability of the *T.b. brucei* parasite to 23.3 – 37.9% with the most active compound **9d** having an IC₅₀ value of 27.88 μM. While some of the 3-[1-(benzylidenehydrazono)ethyl]-4-hydroxycoumarins (**13**) exhibited a measure of trypanocidal activity, compound **13g** was notable, decreasing *T.b. brucei* viability to 1.53% and exhibiting an IC₅₀ value of 0.90 μM. Compound **13g** was also the only compound observed to exhibit, albeit weakly, anti-mycobacterial (anti-TB) activity with MIC₉₀ values of 62.50 μM (visual) and 62.44 μM (calculated).




Figure 2. 400 MHz COSY NMR spectrum of compound **13f** in DMSO- d_6 .




Figure 3. Partial HSQC NMR spectrum of compound **13f** in DMSO- d_6 .

Conclusions

Convenient synthetic access has been successfully established to three series of novel 4-hydroxycoumarin derivatives from substituted acetophenone and benzaldehyde precursors. The products contain several biologically important motifs, viz., 4-hydroxycoumarin, imino, hydrazono and alkynyl moieties. Exploratory bioactivity studies have revealed that some of the products exhibit anti-trypanosomal activity, with one of them having an IC₅₀ value as low as of 0.90 μM against the *T.b. brucei* parasite.

Experimental Section

General. Chemicals were purchased from Sigma-Aldrich Chemical Co. and used without further purification. NMR spectra were recorded on Bruker Biospin 600 MHz NMR and AMX 400 MHz spectrometers and chemical shifts were calibrated relative to the residual proton signal in DMSO-*d*₆ (2.5 ppm) and in CDCl₃ (7.26 ppm). IR Spectra were recorded on a Perkin Elmer Spectrum 100 FTIR spectrometer with a diamond window. Melting points were determined using a Stuart SMP30 apparatus apparatus and are uncorrected. HRMS analyses were conducted at Rhodes University and by the Central Analytical Facilities Unit at the University of Stellenbosch.

The 3-acetyl-4-hydroxycoumarins **7a**,²² **7b**,²⁷ **7c**,²⁸ **7d**,²⁹ **7e**,³⁰ and **7f**,³¹ 3-(1-hydrazonoethyl)-4-hydroxycoumarin **12**,³² the 4-(benzyloxy)benzaldehydes **11a**,³³ **11b**,³⁴ **11c**,³⁵ **11d**,³⁶ and **11e-11g** (commercial compounds from Sigma-Aldrich) and the propargyloxy benzaldehydes **14a**,³⁷ **14b**,³⁸ **14c**,³⁹ **14d**,⁴⁰ **14e**,³⁹ **14f**,⁴¹ and **14g**,⁴² are known compounds. Synthetic procedures for new compounds are provided below. The Supporting Information File contains NMR spectra for new compounds and *in vitro* bioassay protocols and data.

The synthesis of the 3-[1-(*N*-4-benzyloxyphenyl)iminoethyl]-4-hydroxycoumarins (9a-f) is illustrated by the following example.

A mixture of 3-acetyl-4-hydroxycoumarin **7a** (0.10 g, 0.5 mmol) and 4-(benzyloxy)aniline **8** (0.1 g, 0.5 mmol) was dissolved in ethanol (5 mL) and one drop of 2N-HCl was added, after which the mixture was refluxed for at least 1 hour, then cooled and filtered to collect the resulting precipitate which was washed with MeOH and dried to yield **3-[1-(*N*-4-benzyloxyphenyl)iminoethyl]-4-hydroxycoumarin 9a** as a white crystalline product (0.18 g, 93%), m.p. 136-137 °C; [HRMS: *m/z* calculated for C₂₄H₂₀NO₄ (MH⁺) 386.1392. Found 386.1395]; ν_{max}/cm⁻¹ 1710 (C=O); δ_H (400 MHz; CDCl₃) 2.54 (3H, s, CH₃), 4.98 (2H, s, PhCH₂), 6.90-6.95 (2H, m, ArH), 6.99-7.04 (2H, m, ArH), 7.09-7.16 (2H, m, ArH), 7.24 (1H, m, ArH), 7.27-7.35 (4H, m, ArH), 7.44 (1H, ddd, *J* = 8.7, 7.3, 1.8 Hz, ArH) and 7.95 (1H, dd, *J* = 7.8, 1.8 Hz, ArH); δ_C (100 MHz; CDCl₃) 20.9 (CH₃), 70.5 (PhCH₂), 98.0 (C-3), 115.8, 116.8, 120.3, 123.7, 126.1, 126.9, 127.6, 128.4, 128.8, 129.2, 134.2, 136.4, 154.0 and 158.6 (Ar-C), 162.6 (C=O), 176.3 (C=N) and 181.9 (C-OH).

3-[1-(*N*-4-Benzyloxyphenyl)iminoethyl]-6-fluoro-4-hydroxycoumarin 9b as a white crystalline product (0.19 g, 94%), m.p. 145-147 °C; [HRMS: *m/z* calculated for C₂₄H₁₉FNO₄ (MH⁺) 404.1298. Found 404.1296]; ν_{max}/cm⁻¹ 1702 (C=O); δ_H (400 MHz; CDCl₃) 2.53 (3H, s, NCH₃), 4.97 (2H, s, PhCH₂), 6.92 (2H, d, *J* = 8.9 Hz, ArH), 7.00 (2H, d, *J* = 8.8 Hz, ArH), 7.06 (1H, dd, *J* = 8.9, 4.3 Hz, ArH), 7.13 (1H, m, ArH), 7.22 (1H, dd, *J* = 8.4, 5.4 Hz, ArH), 7.25-7.34 (4H, m, ArH) and 7.57 (1H, dd, *J* = 8.3, 2.7 Hz, ArH); δ_C (100 MHz; CDCl₃) 20.9 (CH₃), 70.5 (PhCH₂), 97.8 (C-3), 111.4 (d, ²*J*_{CF} = 24.2 Hz, C-5), 115.9 and 118.4 (Ar-C), 121.3 (d, ³*J*_{CF} = 7.8 Hz, C-10), 121.7 (d, ²*J*_{CF} = 24.4 Hz, C-7), 126.9, 127.6, 128.4, 128.8, 129.1, 136.4, 150.0 and 158.7 (Ar-C), 158.8 (d, ¹*J*_{CF} = 243.0 Hz, C-6), 162.3 (C=O), 176.5 (C=N) and 180.8 (C-OH).

3-[1-(*N*-4-Benzoyloxyphenyl)iminoethyl]-6-chloro-4-hydroxycoumarin 9c as a white crystalline product (0.19 g, 91%), m.p. 162-163 °C; [HRMS: *m/z* calculated for C₂₄H₁₉ClNO₄ (MH⁺) 420.1003. Found 420.1005]; $\nu_{\max}/\text{cm}^{-1}$ 1695 (C=O); δ_{H} (400 MHz; CDCl₃) 2.66 (3H, s, CH₃), 5.11 (2H, s, PhCH₂), 7.04-7.08 (2H, m, ArH), 7.11-7.20 (3H, m, ArH), 7.35-7.51 (6H, m, ArH) and 8.02 (1H, d, *J* = 2.5 Hz, ArH); δ_{C} (100 MHz; CDCl₃) 21.0 (CH₃), 70.4 (PhCH₂), 97.8 (C-3), 115.9, 118.4, 121.4, 125.7, 126.9, 127.6, 128.4, 128.8, 129.0, 129.3, 134.1, 136.3, 152.3 and 158.7 (Ar-C), 162.1 (C=O), 176.4 (C=N) and 180.5 (C-OH).

3-[1-(*N*-4-Benzoyloxyphenyl)iminoethyl]-6-bromo-4-hydroxycoumarin 9d as a white crystalline product (0.20 g, 86%), m.p. 161-162 °C; [HRMS: *m/z* calculated for C₂₄H₁₉BrNO₄ (MH⁺) 464.0497. Found 464.0497]; $\nu_{\max}/\text{cm}^{-1}$ 1701 (C=O); δ_{H} (400 MHz; CDCl₃) 2.66 (3H, s, CH₃), 5.10 (2H, s, PhCH₂), 7.04-7.16 (5H, m, ArH), 7.35 (1H, m, ArH), 7.38-7.46 (4H, m, ArH), 7.62 (1H, dd, *J* = 8.7, 2.5 Hz, ArH) and 8.17 (1H, d, *J* = 2.2 Hz, ArH); δ_{C} (100 MHz; CDCl₃) 20.9 (CH₃), 70.5 (PhCH₂), 97.9 (C-3), 115.9, 116.6, 118.7, 121.8, 126.9, 127.6, 128.4, 128.8, 129.0, 136.4, 136.9, 152.8 and 158.7 (Ar-C), 162.0 (C=O), 176.4 (C=N) and 180.4 (C-OH).

3-[1-(*N*-4-Benzoyloxyphenyl)iminoethyl]-4-hydroxy-6-methylcoumarin 9e as a white crystalline product (0.19 g, 95%), m.p. 142-144 °C; [HRMS: *m/z* calculated for C₂₅H₂₂NO₅ (MH⁺) 400.1549. Found 400.1548]; $\nu_{\max}/\text{cm}^{-1}$ 1650 (C=O); δ_{H} (400 MHz; CDCl₃) 2.40 (3H, s, CH₃), 2.66 (3H, s, CH₃C=N), 5.10 (2H, s, PhCH₂), 7.05 (2H, m, ArH), 7.10-7.16 (3H, m, ArH), 7.33-7.38 (2H, m, ArH), 7.38-7.46 (4H, m, ArH) and 7.85 (1H, s, ArH); δ_{C} (100 MHz; CDCl₃) 20.9 (CH₃), 20.9 (CH₃C=N), 70.5 (PhCH₂), 98.0 (C-3), 115.8, 116.5, 119.9, 125.8, 126.9, 127.6, 128.3, 128.8, 129.3, 133.3, 135.3, 136.4, 152.1 and 158.5 (Ar-C), 162.8 (C=O), 176.2 (C=N) and 182.0 (C-OH).

3-[1-(*N*-4-Benzoyloxyphenyl)iminoethyl]-4-hydroxy-6-methoxycoumarin 9f as a white crystalline product (0.17 g, 82%), m.p. 136-137 °C; [HRMS: *m/z* calculated for C₂₅H₂₂NO₅ (MH⁺) 416.1498. Found 416.1500]; $\nu_{\max}/\text{cm}^{-1}$ 1691 (C=O); δ_{H} (400 MHz; CDCl₃) 2.66 (3H, s, CH₃), 3.85 (3H, s, OCH₃), 5.10 (2H, s, PhCH₂), 7.05 (2H, m, ArH), 7.11-7.17 (4H, m, ArH), 7.35 (1H, dd, *J* = 8.3, 5.5 Hz, ArH), 7.38-7.46 (4H, m, ArH) and 7.48 (1H, s, ArH); δ_{C} (100 MHz; CDCl₃) 20.9 (CH₃), 55.9 (OCH₃), 70.5 (PhCH₂), 97.9 (C-3), 106.8, 115.9, 118.0, 120.5, 123.0, 126.8, 127.6, 128.3, 128.8, 129.3, 136.4, 148.5, 155.9 and 158.6 (Ar-C), 162.7 (C=O), 176.3 (C=N) and 181.6 (C-OH).

The synthesis of the 3-[[2-(benzyloxy-3-ethoxybenzylidene)hydrazono]ethyl]-4-hydroxycoumarin 13a-g is illustrated by the following example.

A solution of 3-(1-hydrazonoethyl)-4-hydroxycoumarin **12** (0.11 g, 0.5 mmol), 2-(benzyloxy)-3-ethoxybenzaldehyde **11a** (0.13 g, 0.5 mmol) and one drop of 2N HCl in ethanol (5 mL) was refluxed for at least one hour and then cooled to room temperature. The resulting precipitate was filtered off, washed with methanol and air dried to afford **3-[[2-(benzyloxy-3-ethoxybenzylidene)hydrazono]ethyl]-4-hydroxycoumarin 13a** as a yellow solid (0.20 g, 88%) m.p. 190-192 °C; [HRMS: *m/z* calculated for C₂₇H₂₅N₂O₅ (MH⁺) 457.1763. Found 457.1766]; $\nu_{\max}/\text{cm}^{-1}$ 1738 (C=O); δ_{H} (600 MHz; CDCl₃) 1.31 (3H, t, *J* = 7.0 Hz, CH₃CH₂), 2.98 (3H, s, CH₃C=N), 3.93 (2H, q, *J* = 6.9 Hz, CH₃CH₂), 4.94 (2H, s, PhCH₂), 6.84 (1H, d, *J* = 7.5 Hz, ArH), 6.90 (1H, t, *J* = 8.0 Hz, ArH), 7.03 (1H, d, *J* = 8.2 Hz, ArH), 7.07 (1H, t, *J* = 7.5 Hz, ArH), 7.12 (1H, t, *J* = 7.2 Hz, ArH), 7.18 (2H, t, *J* = 7.5 Hz, ArH), 7.22 (2H, d, *J* = 7.2 Hz, ArH), 7.31 (1H, d, *J* = 7.5 Hz, ArH), 7.36 (1H, t, *J* = 7.7 Hz, ArH), 7.89 (1H, d, *J* = 7.7 Hz, ArH) and 8.24 (1H, s, CH=N); δ_{C} (150 MHz; CDCl₃) 15.0 and 17.7 (2xCH₃), 64.5 (CH₃CH₂), 76.0 (PhCH₂), 96.5 (C-3), 116.3, 116.8, 118.1, 120.2, 123.8, 124.6, 126.1, 127.3, 128.6, 128.7, 129.0, 134.3, 136.5 and 148.1 (Ar-C), 151.2 (ArC=N), 152.3 and 153.9 (Ar-C), 162.4 (C=O), 173.1 (CH₃C=N) and 181.6 (C-4).

3-[[2-(Benzyloxy-5-chlorobenzylidene)hydrazono]ethyl]-4-hydroxycoumarin 13b as a yellow solid (0.19 g, 85%), m.p. 230-232 °C; [HRMS: *m/z* calculated for C₂₅H₂₀ClN₂O₄ (MH⁺) 447.1112. Found 447.1111]; $\nu_{\max}/\text{cm}^{-1}$ 1694 (C=O); δ_{H} (600 MHz; CDCl₃) 2.98 (3H, s, CH₃), 5.08 (2H, s, PhCH₂), 6.83 (1H, d, *J* = 8.9 Hz, ArH), 7.14 (1H, m, ArH), 7.17 (1H, d, *J* = 7.6 Hz, ArH), 7.25 (1H, dd, *J* = 8.9, 2.6 Hz, ArH), 7.28-7.37 (5H, m, ArH), 7.48 (1H, t, *J* = 7.7 Hz, ArH), 7.88 (1H, d, *J* = 2.6 Hz, ArH), 7.94 (1H, d, *J* = 7.8 Hz, ArH) and 8.64 (1H, s, CH=N); δ_{C} (150 MHz; CDCl₃)

17.9 (CH₃), 71.1 (PhCH₂), 96.8 (C-3), 114.4, 116.8, 120.1, 122.9, 123.9, 126.0, 126.7, 126.8, 127.7, 128.7, 129.0, 133.0, 134.5, 135.7 (Ar-C), 149.3 (ArC=N), 154.0 and 156.7 (Ar-C), 162.3 (C=O), 173.7 (CH₃C=N) and 181.9 (C-4).

3-[[2-(Benzyloxy-5-bromobenzylidene)hydrazono]ethyl]-4-hydroxycoumarin 13c as a yellow solid (0.19 g, 77%), m.p. 232-234 °C; [HRMS: *m/z* calculated for C₂₅H₂₀BrN₂O₄ (MH⁺) 491.0606. Found 491.0608]; $\nu_{\max}/\text{cm}^{-1}$ 1686 (C=N); δ_{H} (600 MHz; CDCl₃) 2.98 (3H, s, CH₃) 5.09 (2H, s, PhCH₂), 6.79 (1H, d, *J* = 8.9 Hz, ArH), 7.13-7.19 (2H, m, ArH), 7.28-7.36 (5H, m, ArH), 7.39 (1H, dd, *J* = 8.8, 2.3 Hz, ArH), 7.48 (1H, t, *J* = 7.7 Hz, ArH) 7.95 (1H, d, *J* = 7.5 Hz, ArH), 8.02 (1H, d, *J* = 2.2 Hz, ArH) and 8.64 (1H s, CH=N); δ_{C} (150 MHz; CDCl₃) 17.9 (CH₃), 71.1 (PhCH₂), 96.8 (C-3), 114.0, 114.8, 116.9, 120.1, 123.5, 123.9, 126.1, 126.7, 128.7, 129.1, 129.8, 134.5, 135.7 and 135.8 (Ar-C), 149.2 (ArC=N), 154.0 and 157.2 (Ar-C), 162.2 (C=O), 173.7 (CH₃C=N) and 181.9 (C-4).

3-[[2-(Benzyloxy-3,5-dibromobenzylidene)hydrazono]ethyl]-4-hydroxycoumarin 13d as a yellow solid (0.22 g, 77%), m.p. 219-221 °C; [HRMS: *m/z* calculated for C₂₅H₁₉Br₂N₂O₄ (MH⁺) 568.9712. Found 568.9719]; $\nu_{\max}/\text{cm}^{-1}$ 1694 (C=O); δ_{H} (600 MHz; CDCl₃) 2.84 (3H, s, CH₃) 4.95 (2H, s, PhCH₂), 7.10-7.17 (2H, m, ArH), 7.20 (1H, m, ArH), 7.24-7.29 (4H, m, ArH), 7.46 (1H, t, *J* = 7.1 Hz, ArH), 7.73 (1H, s ArH), 7.83 (1H, s ArH), 7.95 (1H, s, CH=N) and 7.96 (1H, s, ArH); δ_{C} (150 MHz; CDCl₃) 17.8 (CH₃), 77.5 (PhCH₂), 96.9 (C-3), 116.9, 118.3, 119.3, 120.0, 123.9, 126.2, 128.8, 129.1, 129.2, 129.4, 130.4, 134.6, 134.8 and 138.9 (Ar-C), 148.5 (ArC=N), 154.0 and 154.4 (Ar-C), 162.2 (C=O), 173.8 (CH₃C=N) and 181.9 (C-4).

3-[[2,4-(Dihydroxybenzylidene)hydrazono]ethyl]-4-hydroxycoumarin 13e as a yellow solid (0.15 g, 87%), m.p. 238-240 °C; [HRMS: *m/z* calculated for C₁₈H₁₅N₂O₅ (MH⁺) 339.0981. Found 339.0981]; $\nu_{\max}/\text{cm}^{-1}$ 3206 (O-H) and 1669 (C=N); δ_{H} (600 MHz; DMSO-*d*₆) 2.81 (3H, s, CH₃) 6.36 (2H, dd, *J* = 4.3, 2.3 Hz, ArH), 7.20 (1H, d, *J* = 8.2 Hz, ArH), 7.25 (1H, t, *J* = 7.5 Hz, ArH), 7.56-7.60 (2H, m, ArH), 7.90 (1H, d, *J* = 6.6 Hz, ArH), 8.59 (1H s, CH=N), 10.24 and 10.37 (2H, 2xs, 2xOH); δ_{C} (150 MHz; DMSO-*d*₆) 17.1 (CH₃), 95.2 (C-3), 102.4, 116.4, 108.7, 110.4, 116.3, 119.7, 123.7, 125.6, 129.5, 134.2 and 153.1 (Ar-C), 153.2 (ArC=N), 161.4 (Ar-C), 162.9 (C=O), 169.9 (CH₃C=N) and 179.6 (C-4).

3-[[2,3-(Dihydroxybenzylidene)hydrazono]ethyl]-4-hydroxycoumarin 13f as a yellow solid (0.12 g, 71%), m.p. 260-261 °C; [HRMS: *m/z* calculated for C₁₈H₁₅N₂O₅ (MH⁺) 339.0981. Found 339.0983]; $\nu_{\max}/\text{cm}^{-1}$ 3412 (O-H) and 1701 (C=O); δ_{H} (400 MHz; DMSO-*d*₆) 2.86 (3H, s, CH₃) 6.73 (1H, t, *J* = 7.8 Hz, ArH), 6.93 (1H, d, *J* = 7.5 Hz, ArH), 7.23 (2H, 2 coinciding doublets, *J* = 8.2 Hz, ArH), 7.28 (1H, t, *J* = 7.6 Hz, ArH), 7.61 (1H, t, *J* = 7.7 Hz, ArH) 7.92 (1H, d, *J* = 7.2 Hz, ArH), 8.76 (1H s, CH=N), 9.63 and 9.73 (2H, 2xs, 2xOH); δ_{C} (100 MHz; DMSO-*d*₆) 17.3 (CH₃), 95.5 (C-3), 116.4, 117.7, 118.6, 119.2, 119.6, 119.7, 123.9, 125.7, 134.4, 146.0, 147.0 and 153.2 (Ar-C), 153.5 (ArC=N), 161.3 (C=O), 171.2 (CH₃C=N) and 179.9 (C-4).

3-[[3,4-(Dihydroxybenzylidene)hydrazono]ethyl]-4-hydroxycoumarin 13g as yellow solid (0.14 g, 83%), m.p. 285-286 °C; [HRMS: *m/z* calculated for C₁₈H₁₅N₂O₅ (MH⁺) 339.0981. Found 339.0987]; $\nu_{\max}/\text{cm}^{-1}$ 3333 (O-H) and 1684 (C=N); δ_{H} (400 MHz; DMSO-*d*₆) 2.88 (3H, s, CH₃) 6.86 (1H, d, *J* = 8.1 Hz, ArH), 7.15 (1H, dd, *J* = 8.2, 1.8 Hz, ArH), 7.25 (1H, d, *J* = 8.2 Hz, ArH), 7.29 (1H, t, *J* = 7.5 Hz, ArH), 7.33 (1H, d, *J* = 1.8 Hz, ArH), 7.62 (1H, t, *J* = 7.1 Hz, ArH) 7.93 (d, *J* = 6.7 Hz, ArH), 8.48 (1H s, CH=N), 9.50 and 9.89 (2H, 2xs, 2xOH); δ_{C} (100 MHz; DMSO-*d*₆) 17.7 (CH₃), 95.7 (C-3), 114.2, 116.2, 116.8, 120.2, 123.3, 124.2, 124.5, 126.1, 134.7, 146.3, 150.5 and 153.6 (Ar-C), 157.1 (ArC=N), 161.8 (C=O), 171.2 (CH₃C=N) and 180.2 (C-4).

The synthesis of 3-{1-[(propargyloxybenzylidene)hydrazono]ethyl}-4-hydroxycoumarins **15a-g** is illustrated by the following example.

A solution of 3-(1-hydrazonoethyl)-4-hydroxycoumarin **12** (0.22 g, 1 mmol), 4-(propargyloxy)benzaldehyde **14a** (0.17 g, 1.1 mmol) and one drop of 2N-HCl in ethanol (5 mL) was refluxed for at least one hour and then cooled to room temperature. The mixture was filtered to remove the resulting precipitate which was then washed with methanol and dried to afford 4-hydroxy-3-{1-[(4-propargyloxybenzylidene)hydrazono]ethyl}coumarin **15a** as a yellow solid (0.4 g, 83%) m.p. 209-211 °C; [HRMS: *m/z* calculated for C₂₁H₁₇N₂O₄

(MH⁺) 361.1188. Found 361.1191]; $\nu_{\max}/\text{cm}^{-1}$ 1695 (C=O); δ_{H} (400 MHz; CDCl₃) 2.57 (1H, t, J = 2.4 Hz, C≡CH) 3.06 (3H, s, CH₃), 4.76 (2H, d, J = 2.4 Hz, CH₂) 7.06 (2H, d, J = 8.8 Hz, ArH), 7.21-7.28 (2H, m, ArH), 7.56 (1H, t, J = 8.5 Hz, ArH), 7.75 (2H, d, J = 8.8 Hz, ArH), 8.05 (1H, d, J = 9.0 Hz, ArH) and 8.31 (1H, s, CH=N); δ_{C} (100 MHz; CDCl₃) 17.8 (CH₃), 56.1 (CH₂), 76.4 (C≡CH). 77.9 (C≡CH), 95.6 (C-3), 115.6, 116.9, 120.2, 123.8, 126.1, 126.2, 130.4, 134.3 and 154.0 (Ar-C), 154.4 (ArC=N), 160.8 (Ar-C), 162.4 (C=O), 173.1 (CH₃C=N) and 181.7 (C-4).

4-Hydroxy-3-{1-[(2-propargyloxy)benzylidene]hydrazono}ethyl}coumarin **15b** as a pale yellow solid (0.32 g, 89%), m.p. 188-190 °C; [HRMS: m/z calculated for C₂₁H₁₇N₂O₄ (MH⁺) 361.1188. Found 361.1190]; $\nu_{\max}/\text{cm}^{-1}$ 1695 (C=O); δ_{H} (300 MHz; CDCl₃) 2.48 (1H, t, J = 2.4 Hz, C≡CH) 2.96 (3H, s, CH₃), 4.70 (2H, d, J = 2.4 Hz, CH₂) 6.90-7.01 (2H, m, ArH), 7.21-7.28 (2H, m, ArH), 7.36 (1H, t, J = 7.9 Hz, ArH), 7.45 (1H, t, J = 7.7 Hz, ArH), 7.94 (2H, t, J = 7.5 Hz, ArH) and 8.70 (1H, s, CH=N); δ_{C} (75 MHz; CDCl₃) 17.8 (CH₃), 56.4 (CH₂), 76.6 (C≡CH). 77.9 (C≡CH), 96.6 (C-3), 113.0, 116.8, 120.2, 121.9, 122.1, 123.8, 126.1, 127.4, 130.4, 133.4 and 134.3 (Ar-C), 150.8 (ArC=N), 154.0, 157.1 (Ar-C), 162.3 (C=O), 173.3 (CH₃C=N) and 181.7 (C-4).

4-Hydroxy-3-{1-[(3-methoxy-2-propargyloxybenzylidene)hydrazono]ethyl}coumarin **15c** as a pale yellow solid (0.35 g, 90%), m.p. 192-194 °C; [HRMS: m/z calculated for C₂₂H₁₉N₂O₅ (MH⁺) 391.1294. Found 391.1295]; $\nu_{\max}/\text{cm}^{-1}$ 1713 (C=O); δ_{H} (300 MHz; CDCl₃) 2.52 (1H, t, J = 2.4 Hz, C≡CH) 3.08 (3H, s, CH₃), 3.91 (3H, s, CH₃O), 4.87 (2H, d, J = 2.4 Hz, CH₂) 7.04 (1H, d, J = 9.4 Hz, ArH), 7.17 (1H, t, J = 8.0 Hz, ArH), 7.21-7.29 (2H, m, ArH), 7.57 (1H, t, J = 8.5 Hz, ArH), 7.65 (1H, d, J = 9.1 Hz, ArH), 8.08 (1H, d, J = 8.9 Hz, ArH) and 8.85 (1H, s, CH=N); δ_{C} (75 MHz; CDCl₃) 17.9 (CH₃), 56.1 (CH₃O), 60.7 (CH₂), 77.0 (C≡CH). 78.6 (C≡CH), 96.7 (C-3), 115.4, 116.8, 118.4, 120.2, 123.9, 125.2, 126.2, 127.9, 134.4 and 146.9 (Ar-C), 151.7 (ArC=N), 152.9, 154.1 (Ar-C), 162.4 (C=O), 173.5 (CH₃C=N) and 181.9 (C-4).

3-{1-[(3-Ethoxy-2-propargyloxybenzylidene)hydrazono]ethyl}-4-hydroxycoumarin **15d** as a pale yellow solid (0.37 g, 91%), m.p. 202-204 °C; [HRMS: m/z calculated for C₂₃H₂₁N₂O₅ (MH⁺) 405.1450. Found 405.1457]; $\nu_{\max}/\text{cm}^{-1}$ 1705 (C=O); δ_{H} (600 MHz; CDCl₃) 1.30 (3H, t, J = 7.0 Hz, CH₃CH₂) 2.34 (1H, s, C≡CH) 2.88 (3H, s, CH₃), 3.91 (2H, q, J = 6.9 Hz, CH₃CH₂), 4.72 (2H, d, J = 1.8 Hz, CH₂) 6.83 (1H, d, J = 8.0 Hz, ArH), 6.95 (1H, t, J = 8.0 Hz, ArH), 7.03-7.09 (2H, m, ArH), 7.38 (1H, t, J = 7.7 Hz, ArH), 7.44 (1H, d, J = 7.9 Hz, ArH), 7.88 (1H, d, J = 7.8 Hz, ArH) and 8.65 (1H, s, CH=N); δ_{C} (150 MHz; CDCl₃) 14.9 and 17.9 2xCH₃, 60.5 (CH₂), 64.5 (CH₂CH₃), 76.9 (C≡CH). 78.7 (C≡CH), 96.6 (C-3), 116.2, 116.8, 118.1, 120.1, 123.8, 125.1, 126.1, 127.8, 134.3, 146.8 (Ar-C), 151.7 (ArC=N), 152.1, 153.9 (Ar-C) and 162.4 (C=O), 173.4 (CH₃C=N) and 181.8 (C-4).

4-Hydroxy-3-{1-[(5-nitro-2-propargyloxybenzylidene)hydrazono]ethyl}coumarin **15e** as a pale yellow solid (0.35 g, 86%), m.p. 222-224 °C; [HRMS: m/z calculated for C₂₁H₁₆N₃O₆ (MH⁺) 406.1039. Found 406.1035]; $\nu_{\max}/\text{cm}^{-1}$ 1688 (C=O); δ_{H} (400 MHz; CDCl₃) 2.64 (1H, s, C≡CH) 3.09 (3H, s, CH₃), 4.92 (2H, s, CH₂) 7.15-7.24 (3H, m, ArH), 7.56 (1H, t, J = 6.7 Hz, ArH), 8.02 (1H, d, J = 7.4 Hz, ArH), 8.33 (1H, d, J = 8.5 Hz, ArH), 8.73 (1H, s, CH=N) and 8.86 (1H, s, ArH); δ_{C} (100 MHz; CDCl₃) 17.9 (CH₃), 57.2 (CH₂), 76.4 (C≡CH). 78.0 (C≡CH), 97.2 (C-3), 113.1, 117.0, 120.0, 122.7, 123.1, 124.0, 126.1, 128.1, 134.7 and 142.5 (Ar-C), 148.2 (ArC=N), 154.1, 160.7 (Ar-C), 162.1 (C=O), 174.4 (CH₃C=N) and 182.2 (C-4).

3-{1-[(5-Chloro-2-propargyloxybenzylidene)hydrazono]ethyl}-4-hydroxycoumarin **15f** as a pale yellow solid (0.36 g, 91%), m.p. 232-234 °C; [HRMS: m/z calculated for C₂₁H₁₆ClN₂O₄ (MH⁺) 395.0799. Found 395.0793]; $\nu_{\max}/\text{cm}^{-1}$ 1694 (C=O); δ_{H} (600 MHz; CDCl₃) 2.55 (1H, t, J = 2.4 Hz, C≡CH) 3.04 (3H, s, CH₃), 4.77 (2H, d, J = 2.3 Hz, CH₂) 7.00 (1H, d, J = 8.9 Hz, ArH), 7.18-7.24 (2H, m, ArH), 7.37 (1H, dd, J = 8.9, 2.6 Hz, ArH), 7.54 (1H, t, J = 8.5 Hz, ArH), 7.95 (1H, d, J = 2.6 Hz, ArH), 8.01 (1H, d, J = 7.8 Hz, ArH) and 8.69 (1H, s, CH=N); δ_{C} (150 MHz; CDCl₃) 17.9 (CH₃), 56.8 (CH₂), 77.0 (C≡CH). 77.4 (C≡CH), 96.9 (C-3), 114.5, 116.9, 120.1, 123.4, 123.9, 126.1, 126.8, 127.6, 132.9, 134.5, (Ar-C), 149.3 (ArC=N), 154.1 and 155.5 (Ar-C), 162.3 (C=O), 173.8 (CH₃C=N) and 182.0 (C-4).

3-{1-[(5-Bromo-2-propargyloxybenzylidene)hydrazono]ethyl}-4-hydroxycoumarin 15g as a pale yellow solid (0.39 g, 89%), m.p. 234-235 °C; [HRMS: m/z calculated for $C_{21}H_{16}BrN_2O_4$ (MH^+) 439.0293. Found 439.0298]; ν_{max}/cm^{-1} 1695 (C=O); δ_H (400 MHz; $CDCl_3$) 2.56 (1H, t, $J = 2.2$ Hz, $C\equiv CH$) 3.05 (3H, s, CH_3), 4.77 (2H, d, $J = 2.2$ Hz, CH_2) 6.96 (1H, d, $J = 8.9$ Hz, ArH), 7.17-7.27 (2H, m, ArH), 7.50-7.57 (2H, m, ArH), 8.03 (1H, d, $J = 7.1$ Hz, ArH), 8.10 (1H, d, $J = 2.3$ Hz, ArH) and 8.68 (1H, s, $CH=N$); δ_C (100 MHz; $CDCl_3$) 17.9 (CH_3), 56.7 (CH_2), 77.1 ($C\equiv CH$), 77.4 ($C\equiv CH$), 96.9 (C-3), 114.8, 114.9, 116.9, 120.1, 123.8, 123.9, 126.1, 129.8, 134.5 and 135.8 (Ar-C), 149.2 (ArC=N), 154.1, 156.0 (Ar-C), 162.3 (C=O), 173.8 ($CH_3C=N$) and 182.0 (C-4).

Acknowledgements

The authors thank Rhodes University and the South African Medical Research Council (SAMRC) for generous financial support. This research project was funded by the South African Medical Research Council (SAMRC) with funds from National Treasury under its Economic Competitiveness and Support Package, and Rhodes University Sandisa Imbewu. The authors also acknowledge a Postdoctoral Fellowship (to M.H.M.) supported by the South African Medical Research Council, with funds received from the South African National Department of Health, and the United Kingdom Medical Research Council, with funds received from the United Kingdom Government's Newton Fund.

Supplementary Material

NMR spectra for all new compounds and bioassay protocols and data are provided in the Supporting Information file.

References

1. Sethna, S. M. and Shah, N. M. *Chem. Rev.* **1945**, *36*, (1), 1-62.
<https://doi.org/10.1021/cr60113a001>
2. Küpeli A. E.; Genç, Y.; Karpuz, B.; Sobarzo-Sánchez, E.; Capasso, R. *Cancers (Basel)*. **2020**, *12*, 1959-1984.
<https://doi.org/10.3390/cancers12071959>
3. Ranđelović S, Bipat R. *Clinical Medicine Insights: Endocrinology and Diabetes*. **2021**, *14*, 1-9.
<https://doi.org/10.1177/11795514211042023>
4. Vekariya, R. H.; Patel, H. D. *Synth. Commun.* **2014**, *44*, 2756-2788.
<https://doi.org/10.1080/00397911.2014.926374>
5. Emami, S.; Dadashpour, S. *Eur. J. Med. Chem.* **2015**, *102*, 611-630.
<https://doi.org/10.1016/j.ejmech.2015.08.033>
6. Reddy, N. S.; Gumireddy, K.; Mallireddigari, M. R.; Cosenza, S. C.; Venkatapuram, P.; Bell, S. C.; Reddy, E. P.; Reddy, M. V. R. *Bioorg. Med. Chem.* **2005**, *13*, 3141-3147.
<https://doi.org/10.1016/j.bmc.2005.02.051>
7. Küçükbay F. Z.; Küçükbay H.; Tanc, M.; Supuran C. T.; *J. Enzyme Inhib. Med. Chem.*, **2016**, *31*, 1198-1202.
<https://doi.org/10.3109/14756366.2015.1113173>

8. Antonio, G.-O.; Suarez-Gea, M. L.; Gonzalo, C.-R.; Ramon, L.; Eduardo, R.; Carmen, P.-H.; Ana Isabel, T.-F.; Emilio, V.-C. *Curr. Drug Discov. Technol.* **2012**, *9*, 83-104.
<https://doi.org/10.2174/1570163811209020083>
9. Riveiro, M. E.; De Kimpe, N.; Moglioni, A.; Vazquez, R.; Monczor, F.; Shayo, C.; Davio, C. *Curr. Med. Chem.* **2010**, *17*, 1325-1338.
<https://doi.org/10.2174/092986710790936284>
10. Elhafez, O. M. A.; Khriy, E. E. D. A. M. E.; Badria, F.; Fathy, A. E. D. M. *Arch. Pharm. Res.* **2003**, *26*, 686-696.
<https://doi.org/10.1007/BF02976675>
11. Ali, E.; Naimi-Jamal, M. R.; Dekamin, M. G. *Sci. Iran.* **2013**, *20*, 592-597.
<https://doi.org/10.1016/j.scient.2013.02.007>
12. Bhai, R. D.; Girija, C., & Reddy, K. R. *Journal of Advances in chemistry* **2014**, *10*, 2705-2710.
<https://doi.org/10.24297/jac.v10i5.887>
13. Hameed, A.; al-Rashida, M.; Uroos, M.; Abid Ali, S.; Khan, K. M. *Expert Opin. Ther. Pat.* **2017**, *27*, 63-79
<http://dx.doi.org/10.1080/13543776.2017.1252752>
14. Rollas, S. and Küçükgülzel, S. G. *Molecules* **2007**, *12*, 1910-1939.
<https://doi.org/10.3390/12081910>
15. Correia, C.A.; Gilmore, K.; McQuade, D.T.; Seeberger, P.H. *Angew. Chem. Int. Ed.* **2015**, *54*, 4945-4948.
<https://doi.org/10.1002/anie.201411728>
16. Gupta, B.; Babu, R. B.; Gyanda, K.; Panda, S. S.; Jain, C. S. *Lett. Org. Chem.* **2014**, *11*, 141-144.
<https://dx.doi.org/10.2174/15701786113106660078>
17. Kaye, P. T. S. *Afr. J. Sci.* **2004**, *100*, 545-548.
<https://hdl.handle.net/10520/EJC96190>
18. Olomola, T. O.; Klein, R.; Mautsa, N.; Sayed, Y.; Kaye, P. T. *Bioorg. Med. Chem.* **2013**, *21*, 1964-1971.
<https://doi.org/10.1016/j.bmc.2013.01.025>
19. Olomola, T. O.; Mosebi, S.; Klein, R.; Traut-Johnstone, T.; Coates, J.; Hewer, R.; Kaye, P. T. *Bioorg. Chem.* **2014**, *57*, 1-4.
<https://doi.org/10.1016/j.bioorg.2014.07.008>
20. Olomola, T. O.; Klein, R.; Lobb, K. A.; Sayed, Y.; Kaye, P. T. *Tetrahedron Lett.* **2010**, *51*, 6325-6328.
<https://doi.org/10.1016/j.tetlet.2010.09.121>
21. Manyeruke, M.H.; Tshiwawa, T.; Hoppe, H.C.; Isaacs, M.; Seldon R.; Warner, D.F.; Krause, R.W.M. Kaye, P.T. *Arkivoc* **2022** (v) 159 – 166
<https://doi.org/10.24820/ark.5550190.p011.725>
22. Zhao, P.-L.; Wang, L.; Zhu, X.-L.; Huang, X.; Zhan, C.-G.; Wu, J.-W.; Yang, G.-F. *J. Am. Chem. Soc.* **2010**, *132*, 185-194.
<https://doi.org/10.1021/ja905756c>
23. Sukdolak, S.; Solujić, S.; Manojlović, N.; Vuković, N.; Krstić, L. J. *J. Heterocycl. Chem.* **2004**, *41*, 593-596.
<https://doi.org/10.1002/jhet.5570410418>
24. Ristic, M. N.; Radulovic, N. S.; Dekic, B. R.; Dekic, V. S.; Ristic, N. R.; Stojanovic-Radic, Z. *Chemistry & Biodiversity* **2019**, *16*, e1800486n.
<https://doi.org/10.1002/cbdv.201800486>
25. Batran, R. Z.; Khedr, M. A.; Abdel Latif, N. A.; Abd El Aty, A. A.; Shehata, A. N. *J. Mol. Struct.* **2019**, *1180*, 260-271.
<https://doi.org/10.1016/j.molstruc.2018.11.099>
26. Abdel Latif, N. A.; Batran, R. Z.; Khedr, M. A.; Abdalla, M. M. *Bioorg. Chem.* **2016**, *67*,

- <https://doi.org/10.1016/j.bioorg.2016.06.005>
27. Daněk, O. *Collect. Czech. Chem. Commun.* **1964**, *29*, 1035-1041.
<https://doi.org/10.1135/cccc19641035>
28. Athanasellis, G.; Melagraki, G.; Chatzidakis, H.; Afantitis, A.; Detsi, A.; Igglessi-Markopoulou, O.; Markopoulos, J. *Synthesis* **2004**, *2004*, 1775-1782.
<https://doi.org/10.1055/s-2004-829132>
29. Ziegler, E.; Junek, H. *Monatshefte für Chemie und verwandte Teile anderer Wissenschaften* **1955**, *86*, 506-510.
<https://doi.org/10.1007/Bf00903639>
30. Karia, D.; Manvar, A.; Trangadia, V.; Shah, A. *Ind. J. Org. Chem.* **2007**, *3*, 170-175.
31. Badcock, G. G.; Dean, F. M.; Robertson, A.; Whalley, W. B. *J. Chem. Soc. (Resumed)* **1950**, 903-908.
<https://doi.org/10.1039/JR9500000903>
32. Mustafa, A.; Hishmat, O. H.; Nawar, A. A.; Khalil, K. H. M. A. *Justus Liebigs Annalen der Chemie* **1965**, *684*, 194-200.
<http://dx.doi.org/10.1002/jlac.19656840120>
33. Profft, E. *Journal für Praktische Chemie* **1957**, *5*, 175-181.
<https://doi.org/10.1002/prac.19570050303>
34. Lin, C.-F.; Yang, J.-S.; Chang, C.-Y.; Kuo, S.-C.; Lee, M.-R.; Huang, L.-J. *Bioorg. Med. Chem.* **2005**, *13*, 1537-1544.
<https://doi.org/10.1016/j.bmc.2004.12.026>
35. Pouysegu, L.; Chassaing, S.; Dejugnac, D.; Lamidey, A. M.; Miqueu, K.; Sotiropoulos, J. M.; Quideau, S. *Angew. Chem. Int. Ed. Engl.* **2008**, *47*, 3552-3555.
<https://doi.org/10.1002/anie.200705816>
36. Raiford, L. C.; Tanzer, L. K. *J. Org. Chem.* **1941**, *06*, 722-731.
<https://doi.org/10.1021/jo01205a008>
37. Hans, R. H.; Guantai, E. M.; Lategan, C.; Smith, P. J.; Wan, B.; Franzblau, S. G.; Gut, J.; Rosenthal, P. J.; Chibale, K. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 942-944.
<https://doi.org/10.1016/j.bmcl.2009.12.062>
38. Hu, J.; Zhang, M.; Yu, L. B.; Ju, Y. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 4342-4345.
<https://doi.org/10.1016/j.bmcl.2010.06.079>
39. Khoshkholgh, M. J.; Balalaie, S.; Gleiter, R.; Rominger, F. *Tetrahedron* **2008**, *64*, 10924-10929.
<https://doi.org/10.1002/chin.200911168>
40. Muthusamy, S.; Gangadurai, C. *Tetrahedron Lett.* **2018**, *59*, 1501-1505.
<https://doi.org/10.1016/j.tetlet.2018.03.013>
41. Vedachalam, S.; Wong, Q.-L.; Maji, B.; Zeng, J.; Ma, J.; Liu, X.-W. *Adv. Synth. Catal.* **2011**, *353*, 219-225.
<https://doi.org/10.1055/s-0030-1259847>
42. Janietz, D.; Rudolf, W.-D. *Tetrahedron* **1989**, *45*, 1661-1666.
[https://doi.org/10.1016/S0040-4020\(01\)80030-2](https://doi.org/10.1016/S0040-4020(01)80030-2)

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)